[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Zhao J, Yan LN, Li B: Adult-to-adult living donor liver transplantation for malignant metastatic melanoma to the liver. Hepatobiliary Pancreat Dis Int; 2010 Jun;9(3):329-32
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult-to-adult living donor liver transplantation for malignant metastatic melanoma to the liver.
  • BACKGROUND: Metastases from malignant melanoma to the liver are rare in China, and surgical resection may be of potential benefit.
  • Liver transplantation for this disease has never been reported.
  • METHODS: We report a case of adult-to-adult living donor liver transplantation (A-A LDLT) for metastatic melanoma.
  • With a surgical history of ocular melanoma, the recipient presented with emaciation from a large right hepatic mass which also probably had portal vein invasion.
  • Postoperative pathology confirmed the diagnosis of metastatic malignant melanoma; however no adjuvant chemotherapy was employed after transplantation.
  • We also reviewed the literature on the surgical treatment of metastatic malignant melanoma to the liver and discussed the LDLT indications.
  • CONCLUSIONS: Review of the literature suggested that only a small subset of selected patients may benefit from liver resection.
  • Large metastatic disease in the liver potentially involving a major vessel, as in this case, should be contraindicated for liver transplantation.
  • [MeSH-major] Ciliary Body / pathology. Liver Neoplasms / surgery. Liver Transplantation. Living Donors. Melanoma / surgery. Uveal Neoplasms / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Time Factors. Tomography, X-Ray Computed. Treatment Outcome


2. Okaro AC, Deery AR, Hutchins RR, Davidson BR: The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol; 2001 Dec;54(12):927-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium.
  • The activation of apoptosis is a major mode of action of chemotherapy and radiotherapy, which have limited benefit in the treatment of cholangiocarcinoma.
  • METHODS: The expression of Bcl-2, Bcl-X(L), and Mcl-1 was investigated in normal biliary epithelium (17), biliary dysplasia (three), and invasive cholangiocarcinoma (51), in addition to three human cholangiocarcinoma cell lines, by immunohistochemistry and immunofluorescence.
  • RESULTS: The expression of Bcl-2 was not detected in normal or malignant biliary tissue.
  • In contrast, granular cytoplasmic Bcl-X(L) and Mcl-1 staining was found in 60-100% of cells in all normal, dysplastic, and malignant specimens, including the human cell lines examined in this study.
  • CONCLUSION: These findings indicate that Mcl-1 and Bcl-X(L), but not Bcl-2, are involved in the survival of normal and neoplastic cells in the biliary tree.
  • By prolonging survival through blocking apoptosis, these proteins might be reducing the efficacy of cytotoxic anticancer treatments in cholangiocarcinoma.
  • [MeSH-major] Apoptosis / physiology. Bile Duct Neoplasms / chemistry. Cholangiocarcinoma / chemistry. Neoplasm Proteins / analysis. Precancerous Conditions / chemistry. Proto-Oncogene Proteins c-bcl-2 / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1984 Jan 14;1(8368):66-70 [6197596.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:122-6 [10436802.001]
  • [Cites] J Hepatol. 1985;1(6):579-96 [4056357.001]
  • [Cites] Aust N Z J Surg. 1989 Jan;59(1):25-30 [2536540.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5407-11 [1394146.001]
  • [Cites] Blood. 1993 Jan 1;81(1):151-7 [8417786.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3091-6 [7684624.001]
  • [Cites] Surg Oncol. 1992 Aug;1(4):283-90 [1341262.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):460-5 [8129031.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2576-82 [7780971.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1389-94 [7478561.001]
  • [Cites] Tohoku J Exp Med. 1995 Sep;177(1):61-71 [8693487.001]
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):975-8 [8687162.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4743-8 [8840993.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):463-73; discussion 473-5 [8857851.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1129-32 [9027314.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Annu Rev Neurosci. 1997;20:245-67 [9056714.001]
  • [Cites] Blood. 1997 Mar 15;89(6):1845-53 [9058703.001]
  • [Cites] Australas Radiol. 1997 May;41(2):151-4 [9153812.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1997 Jun;106(6):445-50 [9199601.001]
  • [Cites] J Clin Pathol. 1997 May;50(5):389-93 [9215121.001]
  • [Cites] Hepatology. 1997 Oct;26(4):884-90 [9328309.001]
  • [Cites] J Intern Med Suppl. 1997;740:139-45 [9350196.001]
  • [Cites] Blood. 1998 Feb 1;91(3):991-1000 [9446661.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2321-5 [9635523.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):365-72 [9783782.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14681-6 [9843949.001]
  • [Cites] Am J Clin Oncol. 1999 Feb;22(1):78-81 [10025387.001]
  • [Cites] Nature. 1999 Jun 3;399(6735):483-7 [10365962.001]
  • [Cites] Histopathology. 1999 Jun;34(6):497-501 [10383693.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):108-16 [10398896.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):122-7 [10398898.001]
  • [Cites] Swiss Surg. 1999;5(3):111-5 [10414181.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4495-504 [10442640.001]
  • (PMID = 11729212.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein
  • [Other-IDs] NLM/ PMC1731328
  •  go-up   go-down


3. Mimeault M, Batra SK: Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer. Gut; 2008 Oct;57(10):1456-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.
  • The presence of immature pancreatic cells with stem cell-like properties offers the possibility of stimulating their in vivo expansion and differentiation or to use their ex vivo expanded progenies for beta cell replacement-based therapies for type 1 or 2 diabetes mellitus in humans.
  • In addition, the transplantation of either insulin-producing beta cells derived from embryonic, fetal and other tissue-resident adult stem/progenitor cells or genetically modified adult stem/progenitor cells may also constitute alternative promising therapies for treating diabetic patients.
  • The genetic and/or epigenetic alterations in putative pancreatic adult stem/progenitor cells and/or their early progenies may, however, contribute to their acquisition of a dysfunctional behaviour as well as their malignant transformation into pancreatic cancer stem/progenitor cells.
  • More particularly, the activation of distinct tumorigenic signalling cascades, including the hedgehog, epidermal growth factor-epidermal growth factor receptor (EGF-EGFR) system, wingless ligand (Wnt)/beta-catenin and/or stromal cell-derived factor-1 (SDF-1)-CXC chemokine receptor 4 (CXCR4) pathways may play a major role in the sustained growth, survival, metastasis and/or drug resistance of pancreatic cancer stem/progenitor cells and their further differentiated progenies.
  • The combination of drugs that target the oncogenic elements in pancreatic cancer stem/progenitor cells and their microenvironment, with the conventional chemotherapeutic regimens, could represent promising therapeutic strategies.
  • These novel targeted therapies should lead to the development of more effective treatments of locally advanced and metastatic pancreatic cancers, which remain incurable with current therapies.


Advertisement
4. Sperti C, Berselli M, Pasquali C, Pastorelli D, Pedrazzoli S: Aggressive behaviour of solid-pseudopapillary tumor of the pancreas in adults: a case report and review of the literature. World J Gastroenterol; 2008 Feb 14;14(6):960-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solid-pseudopapillary tumor (SPT) is a rare neoplasm of the pancreas that usually occurs in young females.
  • It is generally considered a low-grade malignant tumor that can remain asymptomatic for several years.
  • The tumor invaded a long segment of the portal-mesenteric vein confluence, and was removed with a total pancreatectomy, resection of the portal vein and reconstruction with the internal jugular vein.
  • The postoperative course was uneventful, but 32 mo after surgery the patient experienced diffuse liver metastases.
  • Chemotherapy with different drugs was started.
  • The best treatment remains a radical resection whenever possible, even in locally advanced or metastatic disease.
  • The role of chemotherapy, and/or radiotherapy, is still to be defined.
  • [MeSH-major] Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Middle Aged. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):887-9 [10919054.001]
  • [Cites] J Surg Oncol. 2007 Jun 15;95(8):640-4 [17477365.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] Pancreatology. 2002;2(5):495-8 [12378119.001]
  • [Cites] ANZ J Surg. 2003 Jun;73(6):410-5 [12801340.001]
  • [Cites] Ann Chir. 2003 Oct;128(8):543-8 [14559306.001]
  • [Cites] J Surg Oncol. 2004 Mar 15;85(4):193-8 [14991875.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):291-3 [15043751.001]
  • [Cites] J Surg Oncol. 1983 Feb;22(2):115-7 [6823124.001]
  • [Cites] Ann Surg. 1983 Mar;197(3):272-5 [6830334.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2783-5 [4052952.001]
  • [Cites] Gastroenterol Jpn. 1987 Jun;22(3):379-84 [2442059.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):283-91 [2295051.001]
  • [Cites] Surgery. 1990 Sep;108(3):475-80 [2396191.001]
  • [Cites] Acta Pathol Jpn. 1991 Oct;41(10):763-70 [1812691.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):82-92 [8416730.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):433-6 [8457156.001]
  • [Cites] Med Pediatr Oncol. 1993;21(5):365-7 [8492753.001]
  • [Cites] Surgery. 1995 Nov;118(5):821-8 [7482268.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(10):789-93 [9587521.001]
  • [Cites] Pathol Int. 1999 Mar;49(3):231-4 [10338079.001]
  • [Cites] Cancer. 1961 Nov-Dec;14:1272-94 [13909709.001]
  • [Cites] Lancet Oncol. 2005 Mar;6(3):185-6 [15737835.001]
  • [Cites] World J Gastroenterol. 2005 Mar 7;11(9):1403-9 [15761986.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):512-9 [15767807.001]
  • [Cites] Pancreatology. 2005;5(2-3):289-94 [15855828.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Aug;4(3):456-9 [16109536.001]
  • [Cites] Pathol Int. 2005 Dec;55(12):792-6 [16287495.001]
  • [Cites] J Surg Res. 2006 Apr;131(2):276-82 [16457845.001]
  • [Cites] Pancreas. 2006 Apr;32(3):276-80 [16628083.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):733-7 [16609955.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1157-63 [16778826.001]
  • [Cites] Pancreatology. 2006;6(4):291-6 [16636602.001]
  • [Cites] JOP. 2006;7(6):635-42 [17095844.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(6):587-90 [17139438.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):639-40 [17149006.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Nov;98(11):809-16 [17198473.001]
  • [Cites] JOP. 2007;8(2):223-7 [17356247.001]
  • [Cites] J Surg Oncol. 2001 Apr;76(4):289-96 [11320522.001]
  • (PMID = 18240360.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2687069
  •  go-up   go-down


5. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H: Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int; 2007 Feb;6(1):92-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of tumor stem cell markers in pancreatic carcinoma cell lines.
  • In malignancy, actively proliferating cells may be effectively targeted and killed by anti-cancer therapies, but stem cells may survive and support re-growth of the tumor.
  • Thus, new strategies for the treatment of cancer clearly will also have to target cancer stem cells.
  • Total RNA was isolated and real-time RT-PCR was performed to determine the expression of ABCG2 and CD133.
  • RESULTS: All pancreatic carcinoma cell lines tested expressed significantly higher levels of ABCG2 than non-malignant fibroblasts or two other malignant non-pancreatic cell lines, i.e., SaOS2 osteosarcoma and SKOV3 ovarian cancer.
  • Because cancer stem cells are thought to be responsible for tumor initiation and its recurrence after an initial response to chemotherapy, they may be a very promising target for new drug developments.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. Adenocarcinoma / metabolism. Antigens, CD / biosynthesis. Biomarkers, Tumor / biosynthesis. Glycoproteins / biosynthesis. Neoplasm Proteins / biosynthesis. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287174.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / AC133 Antigen; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / PROM1 protein, human; 0 / Peptides
  •  go-up   go-down


6. Madanur MA, Battula N, Azam MO, Heaton N, Rela M: Chylous ascites after pancreatico-duodenectomy cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int; 2007 Aug;6(4):416-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CA may be due to a consequence of occult obstruction of the proximal thoracic duct by malignant infiltration or tumor embolus.
  • METHODS: A retrospective search of our liver database was performed using the key words "pancreatico-duodenectomy", "chylous ascites" from January 2000 to December 2005.
  • Two patients developed loco-regional recurrences at a median follow up of 8 months (range 6-10 months).
  • CONCLUSIONS: CA as an uncommon postoperative complication requires frequent paracentesis, prolonged hospital stay, and delayed adjuvant chemotherapy.
  • [MeSH-major] Chylous Ascites / diagnosis. Chylous Ascites / metabolism. Duodenum / surgery. General Surgery / methods. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Pancreas / surgery
  • [MeSH-minor] Aged. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Transplantation. Peritoneum / metabolism. Postoperative Complications. Retrospective Studies

  • Genetic Alliance. consumer health - Chylous Ascites.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690041.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Doval DC, Bhatia K, Pavithran K, Sharma JB, Vaid AK, Hazarika D: Breast carcinoma with metastasis to the gallbladder: an unusual case report with a short review of literature. Hepatobiliary Pancreat Dis Int; 2006 May;5(2):305-7
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma with metastasis to the gallbladder: an unusual case report with a short review of literature.
  • Gallbladder metastases are very rare and usually arise from malignant melanoma, renal cell carcinoma and cervical carcinoma.
  • One month after the operation, she developed acute abdominal pain and underwent cholecystectomy after clinical investigation.
  • Being considered a patient with metastatic breast carcinoma she was subjected to taxane and anthracycline-based palliative chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / secondary. Gallbladder Neoplasms / secondary. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698597.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 15
  •  go-up   go-down


8. Menias CO, Surabhi VR, Prasad SR, Wang HL, Narra VR, Chintapalli KN: Mimics of cholangiocarcinoma: spectrum of disease. Radiographics; 2008 Jul-Aug;28(4):1115-29
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholangiocarcinoma is the second most common primary malignant hepatobiliary neoplasm, accounting for approximately 15% of liver cancers.
  • A wide spectrum of neoplastic and nonneoplastic conditions of the biliary tract may masquerade as cholangiocarcinoma, adding to the complexity of management in patients suspected to have cholangiocarcinoma.
  • Mimics of cholangiocarcinoma constitute a heterogeneous group of entities that includes primary sclerosing cholangitis, recurrent pyogenic cholangitis, acquired immunodeficiency syndrome cholangiopathy, autoimmune pancreatitis, inflammatory pseudotumor, Mirizzi syndrome, xanthogranulomatous cholangitis, sarcoidosis, chemotherapy-induced sclerosis, hepatocellular carcinoma, metastases, melanoma, lymphoma, leukemia, and carcinoid tumors.
  • In most cases, a definitive diagnosis can be established only with histopathologic examination of a biopsy specimen.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Bile Ducts, Intrahepatic / radiography. Carcinoma / diagnosis. Cholangiocarcinoma / diagnosis. Liver Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635632.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


9. Guo XL, Ma NN, Zhou FG, Zhang L, Bu XX, Sun K, Song JR, Li R, Zhang BH, Wu MC, Wei LX: Up-regulation of hTERT expression by low-dose cisplatin contributes to chemotherapy resistance in human hepatocellular cancer cells. Oncol Rep; 2009 Sep;22(3):549-56
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of hTERT expression by low-dose cisplatin contributes to chemotherapy resistance in human hepatocellular cancer cells.
  • The telomerase is specifically activated in most malignant tumors but is usually inactive in normal somatic cells.
  • Furthermore, preincubation of low-dose cisplatin which induced high expression of hTERT help hepatocellular carcinoma SMMC7721 cells survive under the high concentration of anti-cancer drugs.
  • Inhibition of hTERT increased sensitivity of SMMC7721 cells to chemotherapy.
  • Taken together, these results suggested that up-regulation of hTERT expression by low-dose cisplatin is NF-kappaB-dependent and contributes to chemotherapy resistance in human hepatocellular cancer cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Hepatocellular / drug therapy. Cisplatin / pharmacology. Liver Neoplasms / drug therapy. Telomerase / genetics
  • [MeSH-minor] Cell Line, Tumor. DNA Damage. Drug Resistance, Neoplasm. Gene Expression Regulation, Enzymologic. Humans. NF-kappa B / physiology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639202.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Corapçioglu F, Sarper N, Demir H, Güvenç BH, Sözübir S, Akansel G, Berk FS: A child with undifferentiated sarcoma of the liver complicated with bronchobiliary fistula and detected by hepatobiliary scintigraphy. Pediatr Hematol Oncol; 2004 Jul-Aug;21(5):427-33
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A child with undifferentiated sarcoma of the liver complicated with bronchobiliary fistula and detected by hepatobiliary scintigraphy.
  • Undifferentiated (embryonal) sarcoma of the liver (USL) is a rare malignant mesenchymal tumor principally affecting patients of pediatric age.
  • Bronchobiliary fistula is a very rare complication in patients with liver tumor.
  • To the authors' knowledge, this is the first report of a bronchobiliary fistula resulting from tumor invasion in a child with liver sarcoma.
  • A 12-year-old boy was diagnosed to have USL of the right liver lobe, invading the diaphragm.
  • An extended right hepatectomy and total resection of the mass was performed, leaving patchy tumoral invasion of the anterior diaphragmatic surface followed by combined chemotherapy regimen.
  • Six months after the operation, the presence of bilious sputum suggested a bronchobiliary fistula, which was confirmed by hepatobiliary scintigraphy.
  • Hepatobiliary scintigraphy is the useful diagnostic procedure to define bronchobiliary fistula in children with liver tumor and clinical suspicion of bronchobiliary fistula.
  • [MeSH-major] Biliary Tract Diseases / complications. Biliary Tract Diseases / radionuclide imaging. Bronchial Fistula / complications. Bronchial Fistula / radionuclide imaging. Liver Neoplasms / complications. Sarcoma / complications. Technetium Tc 99m Disofenin
  • [MeSH-minor] Child. Humans. Male. Neoplasm, Residual. Reoperation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15205086.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] QTJ2VIW97T / Technetium Tc 99m Disofenin
  •  go-up   go-down


11. Xia R, Chen X: Effects of Danshen injection on the malignant obstructive jaundice in the SD rat model. J Huazhong Univ Sci Technolog Med Sci; 2006;26(6):686-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Danshen injection on the malignant obstructive jaundice in the SD rat model.
  • To observe the effects of Danshen on the growth of hepatocellular carcinoma in the SD rats, a model of malignant obstructive jaundice was established by inoculation of transplanted tumor into the hepatic portal with the walker-256 hepatocarcinoma line, which resulted in the obstruction by the infiltration and metastasis of hepatocellular carcinoma.
  • The liver function, morphological changes and the expressions of PCNA, VEGF and ICAM-1 in carcinoma foci, peri-carcinoma tissues, adjacent lobe (left-internal lobe) and lung tissues were observed after the treatment with the 4 agents.
  • Our results showed that the protective effect of Danshen on liver function was significantly better than that of NS and 5-FU (P<0.01).
  • Danshen also provided protective effect on the morphological damage of liver caused by obstructive jaundice.
  • The expressions of PCNA,VEGF and ICAM-1 PCNA, VEGF and ICAM-1 in carcinoma foci, peri-carcinoma tissues, adjacent lobe (left-internal lobe) and lung tissues were lower than those in control group and InV group, with the differences being significant (P<0.01).
  • It is concluded that Danshen injection not only has protective effects on liver injury caused by obstructive jaundice, but can inhibit the proliferation and growth of hepatocarcinoma, interfere with the vascularization of tumors, prevent recurrence and metastasis of hepatocarcinoma.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Jaundice, Obstructive / drug therapy. Phenanthrolines / therapeutic use
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / complications. Disease Models, Animal. Intercellular Adhesion Molecule-1 / metabolism. Liver / pathology. Liver Neoplasms / complications. Male. Neoplasm Metastasis. Proliferating Cell Nuclear Antigen / metabolism. Rats. Rats, Wistar. Vascular Endothelial Growth Factor A / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ai Zheng. 2003 Dec;22(12):1363-6 [14693071.001]
  • (PMID = 17357489.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Phenanthrolines; 0 / Proliferating Cell Nuclear Antigen; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, rat; 126547-89-5 / Intercellular Adhesion Molecule-1; 79483-68-4 / dan-shen root extract
  •  go-up   go-down


12. Kitami CE, Shimizu T, Sato O, Kurosaki I, Mori S, Yanagisawa Y, Ajioka Y, Hatakeyama K: Malignant islet cell tumor projecting into the main pancreatic duct. J Hepatobiliary Pancreat Surg; 2000;7(5):529-33
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant islet cell tumor projecting into the main pancreatic duct.
  • We report herein a rare case of islet cell tumor showing a unique growth pattern in a patient who developed repeated acute pancreatitis as the tumor's initial symptom.
  • A distal pancreatectomy with splenectomy was performed because the pancreatitis was localized in the distal pancreas and was not controlled by various drug therapies.
  • Grossly, the tumor consisted of two component parts: a markedly infiltrative part in the pancreatic parenchyma, and a papillary elevated part in the MPD.
  • The MPD was obstructed by the tumor spreading widely along the distal MPD.
  • [MeSH-major] Carcinoma, Islet Cell / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Acute Disease. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pancreatectomy. Pancreatitis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180883.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down


13. Burroughs A, Hochhauser D, Meyer T: Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol; 2004 Jul;5(7):409-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum.
  • Hepatocellular carcinoma is the fifth most common malignant disorder and causes nearly 1 million deaths a year worldwide.
  • The only curative treatments are surgical resection or liver transplantation, but only a few patients are eligible for these procedures.
  • Local ablative treatments such as ethanol injection can lengthen survival in selected patients, and radiofrequency ablation also shows promise.
  • Unfortunately, most patients are suitable only for palliative treatment because of the extent of their tumour or background liver disease or both.
  • For these patients, a wide range of therapeutic interventions have been assessed, including transarterial embolisation (with or without chemotherapy), hormone therapy with antioestrogens and androgens, octreotide, interferon, and both arterial and systemic chemotherapy, of which only chemoembolisation improves survival over symptomatic care.
  • In this review, we focus on two ends of the therapeutic spectrum--transplantation, which is highly effective but applicable to only a few patients, and systemic chemotherapy, which is of uncertain benefit but widely applicable.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy. Liver Transplantation
  • [MeSH-minor] Clinical Trials as Topic. Drug Resistance, Neoplasm. Hepatectomy / methods. Humans. Prognosis


14. Baba H, Teramoto K, Kawamura T, Mori A, Imamura M, Arii S: Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol; 2003 Dec;52(6):469-76
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/PURPOSE: Dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) are key enzymes for predicting the efficacy of 5-FU in the treatment of malignant tumors.
  • However, 5-FU is not commonly commonly chosen for chemotherapeutic treatment of hepatocellular carcinoma (HCC) in practice.
  • The aim of this study was to determine the activities of both DPD and TS in HCCs and corresponding liver parenchyma and to assess the correlation between the activities of these enzymes and clinicopathological features.
  • METHODS: The study material comprised 33 pairs of hepatocellular carcinoma and noncancerous liver samples.
  • The DPD and TS activities were quantified by a radiometric enzymatic assay and a 5-fluoro-2'-deoxyuridine-5'- monophosphate (FdUMP) ligand-binding assay, respectively.
  • DPD activity was lower in the HCCs regardless of their clinical features than in the noncancerous liver parenchyma, whereas TS activity was generally lower in HCCs except for those with certain clinical features.
  • HCCs with multiple nodules showed lower DPD activity and those with a diameter of more than 5 cm showed lower TS activity.
  • In the noncancerous liver parenchyma, a gradual decrease in DPD activity and an increase in TS activity were associated with the age of the patient, liver damage and z-factor.
  • CONCLUSIONS: DPD and TS activity may be affected by the clinicopathological status in both the HCC and the corresponding liver parenchyma.
  • Some HCC patients may be good candidates for 5-FU-based chemotherapy based on measurements of tumor levels of DPD and TS.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Dihydrouracil Dehydrogenase (NADP) / metabolism. Liver / enzymology. Liver Neoplasms / enzymology. Thymidylate Synthase / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Female. Fluorouracil / therapeutic use. Hepatitis, Viral, Human / enzymology. Hepatitis, Viral, Human / pathology. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13680162.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Nestler G, Halloul Z, Evert M, Dombrowski F, Lippert H, Meyer F: Myogenous sarcoma of the gallbladder with a hemangiopericytomatous pattern. J Hepatobiliary Pancreat Surg; 2007;14(2):197-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myogenous sarcoma of the gallbladder with a hemangiopericytomatous pattern.
  • Primary sarcoma of the gallbladder is a very rare neoplasm, and there are few instances of its diagnostic and therapeutic management.
  • We describe a 66-year-old male patient with a sarcoma of the gallbladder.
  • He initially underwent a laparoscopic cholecystectomy, converted to an open procedure.
  • Histology showed a primary sarcoma of the gallbladder (NOS).
  • The two surgical interventions were done with no major complications, and a radical resection status was achieved.
  • Histological investigation revealed a malignant mesenchymal tumor lesion, which was classified as a myogenous sarcoma with a hemangiopericytomatous pattern.
  • Palliative chemotherapy was scheduled, but the patient died of advanced tumor recurrence 10 days after this diagnosis.
  • Despite a poor overall prognosis, extensive surgical resection is favored for myogeneous sarcoma of the gallbladder; this procedure is based on precise clarification of the histopathological diagnosis, and can be followed by attempts with radiation of chemotherapy if early diagnosis-finding has failed.
  • This approach allowed, in our patient with this rare neoplasm, a remarkable tumor-free survival of almost 1 year.
  • [MeSH-major] Gallbladder Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Aged. Cholecystectomy. Humans. Immunohistochemistry. Lymph Node Excision. Male. Reoperation. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384914.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Li Q, Gao C, Juzi JT, Hao X: Analysis of 82 cases of retroperitoneal schwannoma. ANZ J Surg; 2007 Apr;77(4):237-40
Genetic Alliance. consumer health - Schwannoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of the study was to improve the diagnosis and treatment of retroperitoneal schwannoma by analysing clinical manifestations and postoperative course of this rare disease.
  • Only in 13 patients (15.9%) a correct preoperative diagnosis was made by either ultrasound-guided biopsy, computed tomography scanning or magnetic resonance imaging.
  • All patients received operative therapy.
  • Sixty patients (73.2%) underwent a total resection; 13 patients (15.9%) subtotal resection, but 9 patients (11.0%) had only an examination and a biopsy.
  • Pathological results showed 81 (98.8%) were benign schwannoma and 1 (1.2%) was a malignant one.
  • The patient with malignant schwannoma died 18 months after the operation because of metastasized disease.
  • However, with the preoperative assessment of ultrasound-guided fine-needle aspiration, computed tomography and magnetic resonance imaging, the accuracy of diagnosis could definitely be improved.
  • Treatment depends solely on surgery.
  • Malignant schwannomas are insensitive to chemotherapy and radiation, resulting in poor prognosis.
  • [MeSH-major] Neurilemmoma / diagnosis. Neurilemmoma / surgery. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388825.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


17. La Quaglia MP, Shorter NA, Blumgart LH: Central hepatic resection for pediatric tumors. J Pediatr Surg; 2002 Jul;37(7):986-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All 3 received neoadjuvant chemotherapy before hepatic resection.
  • CONCLUSION: Central hepatic resection of malignant tumors involving segments IV, V, and VIII is feasible and effective in childhood.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Child, Preschool. Colorectal Neoplasms / pathology. Hepatoblastoma / pathology. Hepatoblastoma / surgery. Humans. Infant. Male. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12077755.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Vennarecci G, Ettorre GM, Giovannelli L, Del Nonno F, Perracchio L, Visca P, Corazza V, Vidiri A, Visco G, Santoro E: Solitary fibrous tumor of the liver. J Hepatobiliary Pancreat Surg; 2005;12(4):341-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the liver.
  • We report a new case of benign solitary fibrous tumor (SFT) of the liver.
  • Ultrasonography and computed tomography showed a large tumor, 20 cm in diameter, in the right lobe of the liver.
  • Microscopic evaluation showed a benign SFT of the liver with tumor cells typically positive for vimentin and CD34.
  • This is a rare neoplasm of mesenchymal origin that occasionally involves the liver in adult patients.
  • Most SFTs are benign, but some may have malignant histological features and recur locally or metastasize.
  • Surgery is the mainstay of treatment.
  • As SFT of the liver is often a benign neoplasm, chemotherapy or radiotherapy should not be necessary, and should be reserved for when resection is incomplete and/or histological examination reveals features of malignancy.
  • Surgeons must be aware of SFT of the liver, and this neoplasm should be included in the differential diagnosis of a single large hepatic mass.
  • [MeSH-major] Liver Neoplasms / pathology. Neoplasms, Fibrous Tissue / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16133706.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Nomura N, Fujii T, Kanazumi N, Takeda S, Nomoto S, Kasuya H, Sugimoto H, Yamada S, Nakao A: Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg; 2009;16(5):639-47
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: We present our experience in the treatment of nonfunctioning neuroendocrine pancreatic tumors (NFNPTs) to define the clinical and pathological characteristics and to suggest proper management.
  • METHODS: The records of 17 patients with NFNPTs operated on between 1998 and 2008 were retrospectively reviewed, and all tumors were classified clinicopathologically as benign, uncertain, and malignant, based on the World Health Organization (WHO) classification of neuroendocrine tumors.
  • RESULTS: There were four benign, six uncertain, and seven malignant NFNPTs.
  • Most of these symptomatic patients had malignant tumors.
  • Mean tumor size of benign, uncertain, and malignant tumors were 1.0 +/- 0.3, 3.2 +/- 1.6, and 5.3 +/- 2.4 cm, respectively.
  • Metastatic lesions of malignant tumors were lymph node (six patients), liver (four patients), and adrenal gland (one patient).
  • Six of seven patients with malignant tumors underwent curative rejection.
  • There were recurrences in four of six patients with curatively rejected malignant tumors.
  • Two patients underwent more rejection, three patients received systemic chemotherapy, and two patients underwent radiofrequency ablation and transcatheter arterial chemoembolization for liver metastases.
  • Survival of patients with malignant tumors was significantly shorter than that of patients with benign and uncertain tumors.
  • However, three patients with malignant tumors had long survival of more than 3 years, even with metastases or recurrences.
  • Even when a tumor was unresectable or there were recurrences, long-time palliation could be achieved by a multidisciplinary approach.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / therapy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Chemotherapy, Adjuvant. Cohort Studies. Female. Follow-Up Studies. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreatectomy / methods. Probability. Retrospective Studies. Risk Assessment. Severity of Illness Index. Statistics, Nonparametric. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365596.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Ortner MA: [Klatskin tumors--diagnostic and interventional therapy]. Praxis (Bern 1994); 2006 Oct 18;95(42):1637-42
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Klatskin tumors--diagnostic and interventional therapy].
  • [Transliterated title] Klatskin-Tumoren--Diagnostik und interventionelle Therapie.
  • Klatskin tumors are defined as malignant tumors of the bile duct involving the bifurcation and intrahepatic bile ducts.
  • Imaging procedures for diagnosis and staging are ultrasonography, magnetic resonance imaging with cholangiopancreaticography, intravenous bolus-enhanced spiral computed tomography and endoscopic retrograde cholangiopancreaticography.
  • Before initiating any palliative measure, a proper staging and a surgical consultation at a hepatobiliary center is necessary.
  • To assess resectability, additional diagnostic methods like angiography, positron emission tomography, cholangioscopy, endoscopic or intraluminal ultrasonography and finally even explorative laparoscopy may be required.
  • At time of diagnosis only a small percentage of Klatskin tumors is curative resectable.
  • Therefore, palliative treatment options play an important role.
  • Although it improves quality of life, it does not seem to improve survival time.
  • Definitive evidence for a benefit of additional radio and/or chemotherapy is still missing.
  • Photodynamic therapy, a light therapy, is the first approach leading to an improvement of cholestasis and quality of life as well as to a prolongation of survival time.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Hepatic Duct, Common. Klatskin Tumor / diagnosis
  • [MeSH-minor] Cholangiopancreatography, Endoscopic Retrograde. Diagnostic Imaging. Humans. Neoplasm Staging. Palliative Care. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17111849.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Fan YZ, Fu JY, Zhao ZM, Chen CQ: Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreat Dis Int; 2007 Feb;6(1):72-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gallbladder carcinoma is a lethal malignant neoplasm with dismal surgical results.
  • Unfortunately, the adjuvant therapies for gallbladder carcinoma such as chemotherapy and radiotherapy are also disappointing.
  • METHODS: Human gallbladder carcinoma GBC-SD cells were grown in cell culture and divided into a NCTD group and a control group.
  • RESULTS: NCTD inhibited the proliferation of GBC-SD cells in a dose- and time-dependent manner, with an IC50 of 56.18 microg/ml at 48 hours.
  • The flow cytometric profiles revealed that NCTD (at the IC50 for 48 hours) significantly increased the proportion of cells in G2/M phase and significantly decreased the proportion of cells in S phase, with a significantly increased rate of cell apoptosis.
  • After treatment with the 48-hour IC50 dose of NCTD, cell shrinkage, vacuolar cytoplasm, membrane budding, karyorrhexis, karyolysis, chromosome condensation and chromatin aggregation in some GBC-SD cells were observed by light-microscopy; decreased microvilli, Golgiosome atrophy, mitochondrial swelling, nuclear shrinkage, chromosome condensation and typical apoptosis bodies were seen by electron-microscopy, and the morphological changes of apoptosis occurred in GBC-SD cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Bicyclo Compounds, Heterocyclic / pharmacology. Cell Proliferation / drug effects. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Cell Cycle / drug effects. Humans. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287171.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bicyclo Compounds, Heterocyclic; 5442-12-6 / norcantharidin
  •  go-up   go-down


22. Tang T, Zheng JW, Chen B, Li H, Li X, Xue KY, Ai X, Zou SQ: Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int; 2007 Jun;6(3):303-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice.
  • BACKGROUND: Targeting is a new therapeutic tool for malignant tumor as a result of combining nanotechnology with chemotherapeutics.
  • The aim of our study was to investigate the effects of magnetic nanoparticles enveloping a chemotherapeutic drug on human cholangiocarcinoma xenografts in nude mice.
  • Calculations were made 35 days after treatment in order to compare the volumes, inhibition ratios and growth curves of the tumors in each group.
  • Mice in each group were sacrificed randomly to collect tumor tissues and other organs for electron microscopy and pathological examination.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Cholangiocarcinoma / drug therapy. Fluorouracil / administration & dosage. Magnetics
  • [MeSH-minor] Animals. Bile Ducts, Intrahepatic. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Nanoparticles. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548256.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Mimeault M, Batra SK: Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies. Anticancer Agents Med Chem; 2010 Feb;10(2):137-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.
  • The malignant transformation of tissue-resident adult stem/progenitor cells or their progenies into tumorigenic and migrating cancer stem/progenitor cells and their resistance to current cancer therapies have been associated with their high expression levels of specific oncogenic products and drug resistance-associated molecules.
  • The emphasis is on the growth factor signaling pathways involved in the malignant behavior of prostate and pancreatic cancer stem/progenitor cells and their progenies.
  • Of clinical interest, the potential molecular therapeutic targets to eradicate the tumor- and metastasis-initiating cells and their progenies and develop new effective combination therapies against locally advanced and metastatic epithelial cancers are also described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2009;568:139-49 [19582424.001]
  • [Cites] Neoplasma. 2009;56(5):371-8 [19580337.001]
  • [Cites] PLoS One. 2009;4(8):e6816 [19714243.001]
  • [Cites] Oncol Rep. 2009 Oct;22(4):781-7 [19724856.001]
  • [Cites] Breast Cancer Res. 2009;11(4):R46 [19589136.001]
  • [Cites] Int J Cancer. 2009 Nov 15;125(10):2323-31 [19598259.001]
  • [Cites] Prostate. 2009 Nov 1;69(15):1683-93 [19644960.001]
  • [Cites] Cell Cycle. 2009 Oct 1;8(19):3208-17 [19738435.001]
  • [Cites] Ann Surg. 2009 Nov;250(5):747-53 [19826249.001]
  • [Cites] J Immunol. 2009 Dec 1;183(11):7196-203 [19890041.001]
  • [Cites] PLoS One. 2009;4(12):e8314 [20016813.001]
  • [Cites] Int J Oncol. 2010 Feb;36(2):415-20 [20043076.001]
  • [Cites] Cancer Res. 2010 Jan 1;70(1):338-46 [20028869.001]
  • [Cites] Cancer Biol Ther. 2009 Nov;8(22):2186-93 [19923910.001]
  • [Cites] Lab Invest. 2010 Feb;90(2):234-44 [20010854.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1374-84 [19903903.001]
  • [Cites] Mol Cancer Ther. 2010 Mar;9(3):617-30 [20179163.001]
  • [Cites] Drug Discov Today. 2010 May;15(9-10):354-64 [20338259.001]
  • [Cites] Cancer Lett. 2010 Sep 1;295(1):69-84 [20303649.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 20;371(1):163-7 [18423378.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1655-69 [18471545.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):694-5 [18477795.001]
  • [Cites] Breast Cancer Res. 2008;10(2):R25 [18366788.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4287-95 [18519688.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):2051-65 [18375206.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2846-53 [18539963.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17635-51 [18441325.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Cancer Invest. 2008 Jun;26(5):535-42 [18568776.001]
  • [Cites] Stem Cell Rev. 2008 Spring;4(1):27-49 [18288619.001]
  • [Cites] Genome Biol. 2008;9(5):R83 [18492237.001]
  • [Cites] PLoS One. 2008;3(7):e2637 [18612434.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5658-68 [18632618.001]
  • [Cites] Stem Cells. 2008 Jul;26(7):1818-30 [18467664.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Aug;8(5):431-45 [18690849.001]
  • [Cites] PLoS One. 2008;3(8):e3077 [18728788.001]
  • [Cites] Mutat Res. 2008 Sep-Oct;659(3):221-31 [18495523.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):1991-2006 [18712708.001]
  • [Cites] Cancer Treat Rev. 2008 Oct;34(6):558-67 [18501520.001]
  • [Cites] Breast Cancer Res Treat. 2008 Oct;111(3):419-27 [17965935.001]
  • [Cites] Gut. 2008 Oct;57(10):1456-68 [18791122.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2725-35 [18790753.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7742-9 [18829528.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Nov;134(11):1155-63 [18470535.001]
  • [Cites] BMC Cancer. 2008;8:266 [18803879.001]
  • [Cites] Int Rev Immunol. 2008;27(5):293-319 [18853341.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7461-9 [19010863.001]
  • [Cites] BMC Cancer. 2008;8:304 [18940013.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2289-97 [18820285.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Exp Gerontol. 2008 Nov;43(11):981-5 [18639623.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2008 Nov 18;88(42):2994-8 [19080079.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3008-17 [18802032.001]
  • [Cites] Urol Oncol. 2009 Jan-Feb;27(1):36-41 [19111796.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73 [19116269.001]
  • [Cites] Hum Pathol. 2009 Feb;40(2):252-8 [18835619.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):310-4 [19174553.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):1012-24 [19150350.001]
  • [Cites] J Natl Cancer Inst. 2009 Mar 4;101(5):350-9 [19244169.001]
  • [Cites] Ageing Res Rev. 2009 Apr;8(2):94-112 [19114129.001]
  • [Cites] J Biol Chem. 2009 Mar 13;284(11):7138-48 [19147502.001]
  • [Cites] Cancer Treat Rev. 2009 Apr;35(2):167-74 [19027240.001]
  • [Cites] Cancer Genomics Proteomics. 2008 Nov-Dec;5(6):301-10 [19287071.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2010-21 [19276287.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2400-7 [19276344.001]
  • [Cites] Cell Cycle. 2009 Apr 1;8(7):1053-61 [19270533.001]
  • [Cites] Int J Oncol. 2009 May;34(5):1201-7 [19360333.001]
  • [Cites] Int J Cancer. 2009 Jun 15;124(12):2771-9 [19296540.001]
  • [Cites] Stem Cells Dev. 2009 Apr;18(3):465-73 [18680391.001]
  • [Cites] Prostate. 2009 Jun 1;69(8):827-37 [19204913.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4134-42 [19435900.001]
  • [Cites] J Immunol. 2009 Jun 1;182(11):7287-96 [19454726.001]
  • [Cites] Cancer Treat Rev. 2009 Jun;35(4):335-9 [19131170.001]
  • [Cites] Cancer Immunol Immunother. 2009 Aug;58(8):1185-94 [19048252.001]
  • [Cites] PLoS One. 2009;4(5):e5722 [19478945.001]
  • [Cites] Cell Res. 2009 Jun;19(6):683-97 [19365403.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2147-57 [19528475.001]
  • [Cites] Cell Cycle. 2009 Jul 1;8(13):2005-13 [19550141.001]
  • [Cites] Nat Cell Biol. 2007 Apr;9(4):470-8 [17369819.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3153-61 [17409422.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Mol Cancer. 2007;6:26 [17407576.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3716-24 [17440084.001]
  • [Cites] Pancreas. 2007 May;34(4):429-35 [17446842.001]
  • [Cites] Leukemia. 2007 May;21(5):949-55 [17361218.001]
  • [Cites] Exp Cell Res. 2007 May 15;313(9):1877-85 [17428472.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4244-53 [17483336.001]
  • [Cites] Front Biosci. 2007;12:3273-86 [17485298.001]
  • [Cites] Ann Oncol. 2007 May;18(5):835-43 [17018703.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26 [17368038.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 15;357(4):1084-9 [17466949.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] Histol Histopathol. 2007 Sep;22(9):1043-9 [17523082.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5683-90 [17553900.001]
  • [Cites] J Cell Physiol. 2007 Sep;212(3):572-8 [17541959.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6796-805 [17638891.001]
  • [Cites] Prostate. 2007 Sep 15;67(13):1384-96 [17639507.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 2):S30-5 [17644121.001]
  • [Cites] Clin Pharmacol Ther. 2007 Sep;82(3):252-64 [17671448.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5674-9 [17353904.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Sep;8(9):703-13 [17717515.001]
  • [Cites] Cancer Sci. 2007 Oct;98(10):1512-20 [17645776.001]
  • [Cites] Gut. 2007 Oct;56(10):1460-9 [17872573.001]
  • [Cites] Stem Cell Rev. 2007 Jan;3(1):30-8 [17873379.001]
  • [Cites] Cancer Biol Ther. 2007 May;6(5):763-8 [17592251.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1605-19 [17355951.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8980-4 [17908997.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63 [17911267.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):155-79 [17939301.001]
  • [Cites] J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011 [17979879.001]
  • [Cites] Stem Cells Dev. 2007 Oct;16(5):837-47 [17999604.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3629-37 [17909916.001]
  • [Cites] Mo Med. 2007 Sep-Oct;104(5):408-13; quiz 413-4 [18018527.001]
  • [Cites] J Pathol. 2008 Jan;214(1):25-37 [17973239.001]
  • [Cites] Med Hypotheses. 2008;70(2):387-408 [17658698.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):190-7 [18172311.001]
  • [Cites] Nature. 2008 Jan 17;451(7176):345-9 [18202660.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):380-7 [18219291.001]
  • [Cites] Anticancer Res. 2007 Nov-Dec;27(6B):4149-57 [18229422.001]
  • [Cites] World J Gastroenterol. 2008 Feb 14;14(6):925-30 [18240351.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):153-66 [18242515.001]
  • [Cites] Cancer Treat Rev. 2008 Feb;34(1):61-80 [17826917.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] World J Gastroenterol. 2008 Feb 28;14(8):1274-9 [18300357.001]
  • [Cites] Verh Dtsch Ges Pathol. 2007;91:21-8 [18314592.001]
  • [Cites] Hepatology. 2008 Mar;47(3):919-28 [18275073.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Oncogene. 2008 Mar 13;27(12):1749-58 [17891174.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1804-13 [18347183.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):234-52 [18292464.001]
  • [Cites] Physiol Rev. 2008 Apr;88(2):557-79 [18391173.001]
  • [Cites] J Cell Mol Med. 2008 Apr;12(2):459-70 [18182066.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):673-91 [17786164.001]
  • [Cites] Panminerva Med. 2008 Mar;50(1):3-18 [18427384.001]
  • [Cites] Panminerva Med. 2008 Mar;50(1):65-71 [18427389.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Nat Clin Pract Oncol. 2008 May;5(5):280-90 [18349857.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2813-23 [18451249.001]
  • [Cites] Trends Mol Med. 2005 May;11(5):199-203 [15882606.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4320-33 [15899824.001]
  • [Cites] Expert Opin Ther Targets. 2005 Apr;9(2):383-94 [15934922.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Cell Cycle. 2005 Jun;4(6):772-6 [15917668.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5731-41 [16123806.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):511-32 [16172190.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Cell Prolif. 2005 Dec;38(6):363-74 [16300650.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1480-5 [16432235.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Urol Oncol. 2006 Mar-Apr;24(2):131-40 [16520277.001]
  • [Cites] Laryngoscope. 2006 Mar;116(3):401-6 [16540898.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Cell Mol Life Sci. 2006 Feb;63(4):435-48 [16389455.001]
  • [Cites] Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):11-34 [16569343.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] Urol Clin North Am. 2006 May;33(2):201-10, vii [16631458.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] J Biomed Sci. 2006 May;13(3):373-84 [16374524.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1213-8 [16632344.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2828-35 [16782921.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):164-71 [16804520.001]
  • [Cites] Eur Urol. 2006 Sep;50(3):428-38; discussion 438-9 [16797118.001]
  • [Cites] BMC Cancer. 2006;6:112 [16670021.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8598-607 [16951173.001]
  • [Cites] Prostate. 2006 Sep 15;66(13):1437-44 [16741920.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R210-9 [16987886.001]
  • [Cites] Glia. 2006 Dec;54(8):850-60 [16981197.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1133-8 [17016644.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5615-21 [17020963.001]
  • [Cites] Cancer Biol Ther. 2006 Aug;5(8):901-6 [16855379.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1620-4 [16600978.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2319-45 [16794264.001]
  • [Cites] J Biol Chem. 2006 Nov 17;281(46):34936-41 [16959784.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3161-73 [17114586.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] Eur Urol. 2007 Jan;51(1):17-26 [17007996.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85 [17179479.001]
  • [Cites] Mol Carcinog. 2007 Jan;46(1):1-14 [16921491.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Prostate. 2007 Feb 15;67(3):301-11 [17192875.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2007 Feb;6(1):92-7 [17287174.001]
  • [Cites] Semin Liver Dis. 2007 Feb;27(1):55-76 [17295177.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):203-14 [17273942.001]
  • [Cites] Carcinogenesis. 2007 Apr;28(4):792-800 [17127714.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2870-9 [11555605.001]
  • [Cites] J Pathol. 2001 Dec;195(5):563-70 [11745692.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38013-20 [12145277.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Growth Factors. 2003 Mar;21(1):1-14 [12795332.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):459-77 [14755677.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] J Histochem Cytochem. 2004 Aug;52(8):1083-90 [15258184.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Urol. 2005 Jan;173(1):10-20 [15592017.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):221-36 [15663986.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Med Hypotheses. 2005;64(6):1182-7 [15823713.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • (PMID = 20184544.001).
  • [ISSN] 1875-5992
  • [Journal-full-title] Anti-cancer agents in medicinal chemistry
  • [ISO-abbreviation] Anticancer Agents Med Chem
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA133774-04; United States / NCI NIH HHS / CA / R01 CA078590-13; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA131944-04; United States / NCI NIH HHS / CA / CA133774; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA131944; United States / NCI NIH HHS / CA / CA78590; United States / NCI NIH HHS / CA / CA133774-04; United States / NCI NIH HHS / CA / R01 CA133774; United States / NCI NIH HHS / CA / CA131944; United States / NCI NIH HHS / CA / R01 CA131944-04; United States / NCI NIH HHS / CA / CA111294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers
  • [Number-of-references] 241
  • [Other-IDs] NLM/ NIHMS254312; NLM/ PMC2997522
  •  go-up   go-down


24. Gong LS, Zhang YD, Liu S: Target distribution of magnetic albumin nanoparticles containing adriamycin in transplanted rat liver cancer model. Hepatobiliary Pancreat Dis Int; 2004 Aug;3(3):365-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Target distribution of magnetic albumin nanoparticles containing adriamycin in transplanted rat liver cancer model.
  • BACKGROUND: Liver cancer is one of the most common diseases around the world.
  • The aim of this study was to verify the effect of magnetic field application on target distribution of nanoparticles in transplanted rat liver cancer model and to find out a new method for the treatment of malignant liver tumor.
  • In the experimental group (12 rats), the tumor tissue was exposed to the magnetic field for 30 minutes.
  • Tissues of tumor, nontargeted sites of the liver, heart, kidney, lung, spleen, stomach and small intestine were analyzed for gamma-counts and examined histologically.
  • RESULTS: In the experimental group, the radioactivity of tumor tissue was 8.7 times that of liver tissue.
  • In the control group, the radioactivity of tumor tissue was 2.8 times that of normal liver tissue.
  • And over 80% of the injected nanoparticles distributed in the liver.
  • CONCLUSIONS: In the presence of magnetic field, magnetic albumin nanoparticles may accumulate in tumor tissues, of which the radioactivity can increase to 8.7 times that of normal liver.
  • Even if the magnetic field is not applied, magnetic albumin nanoparticles in tumor tissues still increase to 2.8 times that of normal liver tissues.
  • These findings indicate that normal organs in the presence of magnetic field are less exposed to chemotherapeutic drugs.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Carcinoma 256, Walker / drug therapy. Carcinoma, Hepatocellular / drug therapy. Doxorubicin / pharmacokinetics. Liver Neoplasms / drug therapy
  • [MeSH-minor] Albumins / pharmacokinetics. Animals. Disease Models, Animal. Electromagnetic Fields. Hepatic Artery. Magnetics. Male. Neoplasm Transplantation. Particle Size. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313670.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Albumins; 0 / Antimetabolites, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


25. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One; 2008 Jul 09;3(7):e2637
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein we report the isolation of CD133-positive cells (LC-CD133(+)) and CD133-negative cells (LC-CD133(-)) from tissue samples of ten patients with non-small cell lung cancer (LC) and five LC cell lines.
  • Furthermore, LC-CD133(+), unlike LC-CD133(-), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy.
  • The treatment of Oct-4 siRNA with lentiviral vector can specifically block the capability of LC-CD133(+) to form spheres and can further facilitate LC-CD133(+) to differentiate into LC-CD133(-).
  • Finally, in vitro and in vivo studies further confirm that the treatment effect of chemoradiotherapy for LC-CD133(+) can be improved by the treatment of Oct-4 siRNA.
  • Future research is warranted regarding the up-regulated expression of Oct-4 in LC-CD133(+) and malignant lung cancer.
  • [MeSH-major] Antigens, CD / analysis. Glycoproteins / analysis. Lung Neoplasms / metabolism. Neoplastic Stem Cells / metabolism. Octamer Transcription Factor-3 / metabolism. Peptides / analysis
  • [MeSH-minor] AC133 Antigen. ATP Binding Cassette Transporter, Sub-Family G, Member 2. ATP-Binding Cassette Transporters / metabolism. Apoptosis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Line, Tumor. Cell Survival. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Proteins / metabolism. RNA, Small Interfering / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Jul 19;448(7151):313-7 [17554338.001]
  • [Cites] Respirology. 2007 Jul;12(4):471-7 [17587411.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1917-20 [18029452.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):141-6 [18157115.001]
  • [Cites] Stem Cells. 2008 Jan;26(1):30-4 [17932422.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):361-70 [14667503.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):965-9 [15333659.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Nature. 1990 Jun 21;345(6277):686-92 [1972777.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1797-806 [8666936.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12873-8 [8662786.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Mol Reprod Dev. 1998 Oct;51(2):218-24 [9740330.001]
  • [Cites] Cell. 1998 Oct 30;95(3):379-91 [9814708.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):104-12 [10077160.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1770-7 [15753373.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5410-6 [16061855.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Nov;6(11):872-84 [16227977.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):291-301 [16450219.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):295-305 [18297062.001]
  • [Cites] PLoS One. 2008;3(5):e2090 [18509505.001]
  • [Cites] Biochem J. 2003 Oct 1;375(Pt 1):199-205 [12841847.001]
  • [Cites] Oncogene. 2001 Dec 6;20(56):8085-91 [11781821.001]
  • [Cites] Trends Cell Biol. 2002 Sep;12(9):432-8 [12220864.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3052-7 [12912956.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9530-5 [16772384.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2223-35 [17148683.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2007 Feb;6(1):92-7 [17287174.001]
  • [Cites] PLoS One. 2007;2(2):e243 [17327908.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):935-46 [17320377.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2542-56 [17570225.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4137-45 [17827464.001]
  • (PMID = 18612434.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / AC133 Antigen; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / PROM1 protein, human; 0 / Peptides; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC2440807
  •  go-up   go-down


26. Qu B, Guo L, Ma J, Lv Y: Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system. Med Hypotheses; 2010 Feb;74(2):360-1
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system.
  • Antiangiogenesis therapy is one of the most promising approaches to cancer treatment.
  • Vasculogenic mimicry (VM) as an alternative circulatory system, has been described in multiple malignant tumor types, and considered to be associated with a poor prognosis for the patient.
  • VM serves as an adjunct to the existing vasculature system, thereby aiding tumor growth as well as contributing to the metastatic process.
  • As a result, antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing VM.
  • Thus, treatment strategies that target the tumor microcirculation should not only target endothelium-dependent vessels, but also take VM into account in tumors presenting VM.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / adverse effects. Neoplasm Metastasis / physiopathology. Neoplasms / chemically induced. Neoplasms / drug therapy. Neoplastic Cells, Circulating / metabolism. Neovascularization, Pathologic / chemically induced
  • [MeSH-minor] Humans. Microcirculation / drug effects. Models, Biological

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744799.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  •  go-up   go-down






Advertisement